Double versus Single High-Dose Melphalan 200 mg/m2 and Autologous Stem Cell Transplantation for Multiple Myeloma: A Region-Based Study in 484 Patients from the Nordic AREa
Abstract
Share and Cite
Björkstrand, B.; Klausen, T.W.; Remes, K.; Gruber, A.; Knudsen, L.M.; Bergmann, O.J.; Lenhoff, S.; Johnsen, H.E. Double versus Single High-Dose Melphalan 200 mg/m2 and Autologous Stem Cell Transplantation for Multiple Myeloma: A Region-Based Study in 484 Patients from the Nordic AREa. Hematol. Rev. 2009, 1, e2. https://doi.org/10.4081/hr.2009.e2
Björkstrand B, Klausen TW, Remes K, Gruber A, Knudsen LM, Bergmann OJ, Lenhoff S, Johnsen HE. Double versus Single High-Dose Melphalan 200 mg/m2 and Autologous Stem Cell Transplantation for Multiple Myeloma: A Region-Based Study in 484 Patients from the Nordic AREa. Hematology Reviews. 2009; 1(1):e2. https://doi.org/10.4081/hr.2009.e2
Chicago/Turabian StyleBjörkstrand, Bo, Tobias W. Klausen, Kari Remes, Astrid Gruber, Lene M. Knudsen, Olav J. Bergmann, Stig Lenhoff, and Hans E. Johnsen. 2009. "Double versus Single High-Dose Melphalan 200 mg/m2 and Autologous Stem Cell Transplantation for Multiple Myeloma: A Region-Based Study in 484 Patients from the Nordic AREa" Hematology Reviews 1, no. 1: e2. https://doi.org/10.4081/hr.2009.e2
APA StyleBjörkstrand, B., Klausen, T. W., Remes, K., Gruber, A., Knudsen, L. M., Bergmann, O. J., Lenhoff, S., & Johnsen, H. E. (2009). Double versus Single High-Dose Melphalan 200 mg/m2 and Autologous Stem Cell Transplantation for Multiple Myeloma: A Region-Based Study in 484 Patients from the Nordic AREa. Hematology Reviews, 1(1), e2. https://doi.org/10.4081/hr.2009.e2